Using our Guardian Angel™ Artificial Intelligence algorithm, we are precisely matching drugs to diseases and identifying the best care for individual patients. We have demonstrated the Guardian Angel™ power by matching 85% of the world’s approved drugs to their indications.
AI-driven drug development means we skip long R&D cycles, getting life-saving drugs to patients faster. Drugs currently in our clinical trials target lymphangioleiomyomatosis, B-cell non-Hodgkin lymphoma, acute myeloid leukemia, amyotrophic lateral sclerosis, and facial angiofibroma.
A clinical trial is a carefully supervised research study conducted in human volunteers to evaluate an experimental drug that has not yet been made available to the general public. Clinical trials play an important role in the approval of a new medicine by demonstrating that it can effectively treat patients at a safe dose. AI Therapeutics’ clinical trials are taking place at multiple sites across the United States.